Start-up trends, COVID variants and J&J’s adcomm: a BioCentury podcast

In the latest BioCentury This Week podcast, BioCentury editors discuss trends among the latest crop of emerging companies, strategies companies are taking to get ahead of COVID-19 variants, and the potential J&J’s upcoming advisory committee meeting holds in shaping public opinion on COVID-19 vaccines. 

Associate Editor Virginia Li highlights newcos Ensoma and Quell Therapeutics Ltd. and how they fit into broader themes among companies developing next-generation gene and cell therapies, while Associate Editor Stephen Hansen discusses Tuesday’s launch of Centessa, which has bundled 10 single-asset Medicxi companies under one umbrella...